Credit Suisse Ag Point Biopharma Global Inc. Transaction History

Credit Suisse Ag

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$6.67 - $9.71 $67,607 - $98,420	-10,136 Reduced 10.68%	84,763 $565,000
Q2 2023 Aug 11, 2023	BUY	$6.86 - $10.86 $241,458 - $382,250	35,198 Added 58.96%	94,899 $859,000
Q1 2023 May 10, 2023	BUY	$6.78 - $8.1 $42,449 - $50,714	6,261 Added 11.72%	59,701 $434,000
Q4 2022 Feb 13, 2023	BUY	$5.72 - $9.78 $142,845 - $244,235	24,973 Added 87.73%	53,440 $389,000
Q3 2022 Nov 10, 2022	BUY	$7.24 - $10.31 $31,407 - $44,724	4,338 Added 17.98%	28,467 $220,000
Q2 2022 Aug 12, 2022	BUY	$5.6 - $9.5 $5,605 - $9,509	1,001 Added 4.33%	24,129 $164,000
Q1 2022 May 16, 2022	BUY	$5.46 - $8.13 $8,228 - $12,251	1,507 Added 6.97%	23,128 $184,000
Q4 2021 Feb 14, 2022	BUY	$4.83 - $9.75 $104,429 - $210,804	21,621 New	21,621 $120,000

20K

Ticker PNT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 104,025,000
Description
POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate canc...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.